Figure 5 from Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmaco*kinetic Modeling Study | Semantic Scholar (2024)

Table of Contents
Figures and Tables from this paper Ask This PaperBETAAI-Powered 31 References Related Papers References

Skip to search formSkip to main contentSkip to account menu

Semantic ScholarSemantic Scholar's Logo
@article{Bettonte2024DrugEO, title={Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmaco*kinetic Modeling Study}, author={Sara Bettonte and Mattia Berton and Felix Stader and Manuel Battegay and Catia Marzolini}, journal={Open Forum Infectious Diseases}, year={2024}, volume={11}, url={https://api.semanticscholar.org/CorpusID:269029607}}
  • Sara Bettonte, Mattia Berton, C. Marzolini
  • Published in Open Forum Infectious… 21 March 2024
  • Medicine

Virtual studies using physiologically based pharmaco*kinetic (PBPK) modeling determine the anticipated exposure and trough concentrations of LA cabotegravir/rilpivirine in older individuals and suggest older adults could have a lower risk to present suboptimal concentrations during the dosing interval.

Figures and Tables from this paper

  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 3
  • figure 4
  • figure 5

Ask This Paper

BETA

AI-Powered

Our system tries to constrain to information found in this paper. Results quality may vary. Learn more about how we generate these answers.

Feedback?

31 References

Repository Describing an Aging Population to Inform Physiologically Based Pharmaco*kinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
    Felix StaderM. SiccardiM. BattegayHannah KinvigM. PennyC. Marzolini

    Medicine

    Clinical Pharmaco*kinetics

  • 2018

The developed repository for aging subjects provides a singular specific source for key system parameters needed for physiologically based pharmaco*kinetic modeling and can in turn be used to investigate drug kinetics and drug–drug interaction magnitudes in the elderly.

  • 46
  • Highly Influential
  • PDF
Tail-phase safety, tolerability, and pharmaco*kinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    R. LandovitzSue Li C. Hendrix

    Medicine

    The lancet. HIV

  • 2020
  • 81
  • Highly Influential
  • PDF
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
    A. CutrellJ. Schapiro J. van Lunzen

    Medicine

    AIDS

  • 2021

CVF is an infrequent multifactorial event, with a rate of approximately 1% in the long-acting CAB+RPV arms across Phase 3 studies (FLAIR, ATLAS and ATLAS-2M) through Week 48, and these findings support the use of long- acting CAB-RPV in routine clinical practice.

  • 75
  • Highly Influential
  • PDF
Effect of ageing on antiretroviral drug pharmaco*kinetics using clinical data combined with modelling and simulation
    Felix StaderPerrine Courlet C. Marzolini

    Medicine

    British journal of clinical pharmacology

  • 2020

Whether ageing leads to clinically relevant pharmaco*kinetic changes of antiretrovirals that would support a dose adjustment based on the age of the treated PLWH is investigated.

  • 15
  • Highly Influential
  • PDF
Development of a physiologically-based pharmaco*kinetic model to simulate the pharmaco*kinetics of intramuscular antiretroviral drugs.
    Sara BettonteMattia BertonM. BattegayFelix StaderC. Marzolini

    Medicine

  • 2024

The developed framework correctly described the release and the drug disposition of LA formulations upon intramuscular administration and can be implemented in PBPK models to address pharmacological questions related to the use of LA formulations.

  • 1
  • PDF
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen
    Sara BettonteMattia BertonFelix StaderM. BattegayC. Marzolini

    Medicine

    British journal of clinical pharmacology

  • 2023

Intramuscular cabotegravir/rilpivirine (IM CAB/RPV) are metabolized by UGT1A1/CYP3A4. Efavirenz induces both enzymes; therefore, switching from an efavirenz‐containing regimen to IM CAB/RPV could…

  • 2
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies.
    A. TrickeyC. Sabin J. Sterne

    Medicine

    The lancet. HIV

  • 2023
  • 38
  • PDF
Long‐acting injectable Cabotegravir: How drug concentrations could help guide patient management
    J. Castillo-MancillaP. Anderson

    Medicine

    British journal of clinical pharmacology

  • 2022

With the introduction of long-acting (LA) injectable antiretrovirals, a new paradigm for HIV prevention and treatment is upon us. In the last 15months, the Food and Drug Administration-approved LA…

  • 2
  • PDF
A population pharmaco*kinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP
    Yifan YuK. Bigos E. Weld

    Medicine

    British journal of clinical pharmacology

  • 2022

The aim of this study is to describe the population pharmaco*kinetics of long‐acting cabotegravir (CAB‐LA) and describe the variability between individuals and between injection occasions.

  • 5
  • PDF

...

...

Related Papers

Showing 1 through 3 of 0 Related Papers

    Figure 5 from Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmaco*kinetic Modeling Study | Semantic Scholar (9)

    Figure 5. Fold change in exposure (at steady-state administration) in young (aged 20–50 years) female relative to young male individuals and older (aged 65–85 years) female relative to older male adults for long-acting…

    Published in Open Forum Infectious Diseases 2024

    Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmaco*kinetic Modeling Study

    Sara BettonteMattia BertonFelix StaderM. BattegayC. Marzolini

    Figure 8 of 8

    Figure 5 from Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmaco*kinetic Modeling Study | Semantic Scholar (2024)

    References

    Top Articles
    Unraveling the Reverse Cowgirl: An Engaging Guide - Nick Lachey
    9 Ways to Make Reverse Cowgirl Position Feel As Good As It Looks
    Craigslist Boats Space Coast
    Uncc Software
    Latest Posts
    Erin P. Ward [u6045212]
    Thomas K. Varghese Jr. [u6001828]
    Article information

    Author: Duane Harber

    Last Updated:

    Views: 5367

    Rating: 4 / 5 (71 voted)

    Reviews: 86% of readers found this page helpful

    Author information

    Name: Duane Harber

    Birthday: 1999-10-17

    Address: Apt. 404 9899 Magnolia Roads, Port Royceville, ID 78186

    Phone: +186911129794335

    Job: Human Hospitality Planner

    Hobby: Listening to music, Orienteering, Knapping, Dance, Mountain biking, Fishing, Pottery

    Introduction: My name is Duane Harber, I am a modern, clever, handsome, fair, agreeable, inexpensive, beautiful person who loves writing and wants to share my knowledge and understanding with you.